Gradient Investments LLC Incyte Corp Transaction History

Gradient Investments LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$56.55 - $66.59 $1,017 - $1,198	-18 Reduced 10.47%	154 $8,000
Q2 2023 Jul 11, 2023	BUY	$60.95 - $75.51 $1,097 - $1,359	18 Added 11.69%	172 $10,000
Q1 2020 Apr 07, 2020	SELL	$63.18 - $85.97 $252 - $343	-4 Reduced 2.53%	154 $11,000
Q3 2019 Oct 10, 2019	SELL	$72.82 - $86.52 $980,084 - $1.16 Million	-13,459 Reduced 98.84%	158 $12,000
Q2 2019 Jul 16, 2019	BUY	$73.52 - $88.7 $437,517 - $527,853	5,951 Added 77.63%	13,617 $1.16 Million
Q1 2019 Apr 11, 2019	SELL	$63.56 - $88.17 $186,866 - $259,219	-2,940 Reduced 27.72%	7,666 $659,000
Q4 2018 Jan 18, 2019	BUY	$58.5 - $69.94 $620,451 - $741,783	10,606 New	10,606 $674,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Gradient Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Gradient Investments LLC with notifications on news.